Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM. Buckstein R, et al. Among authors: mamedov a. Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15. Br J Haematol. 2016. PMID: 26991631 Free article. Clinical Trial.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R. Houston BL, et al. Among authors: mamedov a. Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3. Ann Hematol. 2017. PMID: 28975386
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.
Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R. Starkman R, et al. Among authors: mamedov a. Leukemia. 2020 May;34(5):1394-1406. doi: 10.1038/s41375-019-0666-7. Epub 2019 Dec 6. Leukemia. 2020. PMID: 31811236
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, McQuilten Z, Wood EM, Weinkov R, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Buckstein R, et al. Among authors: mamedov a. Am J Hematol. 2024 Mar;99(3):473-476. doi: 10.1002/ajh.27181. Epub 2023 Dec 21. Am J Hematol. 2024. PMID: 38126081 No abstract available.
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Buckstein R, et al. Among authors: mamedov a. Transfusion. 2024 Feb;64(2):223-235. doi: 10.1111/trf.17721. Epub 2024 Feb 7. Transfusion. 2024. PMID: 38323704 Clinical Trial.
Improvement in quality of life in MDS patients who become transfusion independent after treatment.
Wan BA, Alibhai SMH, Chodirker L, Mozessohn L, Geddes M, Zhu N, Trottier AM, St-Hilaire E, Finn N, Leber B, Khalaf D, Christou G, Sabloff M, Leitch HA, Shamy A, Yee KWL, Storring J, Nevill TJ, Houston BL, Elemary M, Delage R, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: mamedov a. Leuk Lymphoma. 2024 Nov 9:1-10. doi: 10.1080/10428194.2024.2422844. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39520728
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials.
Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, Chu W, Liu SK, Tseng CL, Davidson M, Deabreu A, Mamedov A, Zhang L, Cheung P. Glicksman RM, et al. Among authors: mamedov a. Clin Transl Radiat Oncol. 2024 Aug 16;49:100843. doi: 10.1016/j.ctro.2024.100843. eCollection 2024 Nov. Clin Transl Radiat Oncol. 2024. PMID: 39318680 Free PMC article.
205 results